A phase II trial to evaluate single-dose stereotactic body radiation therapy (SBRT) prior to surgery for early-stage breast carcinoma: SIGNAL (stereotactic image-guided neoadjuvant ablative radiation then lumpectomy) trial

2015 ◽  
Vol 4 (4) ◽  
pp. 423-430 ◽  
Author(s):  
Keegan Guidolin ◽  
Michael Lock ◽  
Brian Yaremko ◽  
Neil Gelman ◽  
Stewart Gaede ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Single Dose ◽  
Breast Carcinoma ◽  
Phase Ii ◽  
Stereotactic Body Radiation Therapy ◽  
Phase Ii Trial ◽  
Early Stage ◽  
Stereotactic Body Radiation ◽  
Image Guided

Excessive Toxicity When Treating Central Tumors in a Phase II Study of Stereotactic Body Radiation Therapy for Medically Inoperable Early-Stage Lung Cancer

2006 ◽  
Vol 24 (30) ◽  
pp. 4833-4839 ◽  
Author(s):  
Robert Timmerman ◽  
Ronald McGarry ◽  
Constantin Yiannoutsos ◽  
Lech Papiez ◽  
Kathy Tudor ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Radiation Therapy ◽  
Phase Ii ◽  
Local Control ◽  
Stereotactic Body Radiation Therapy ◽  
Early Stage ◽  
Stage I ◽  
Severe Toxicity ◽  
Stereotactic Body Radiation

PurposeSurgical resection is standard therapy in stage I non–small-cell lung cancer (NSCLC); however, many patients are inoperable due to comorbid diseases. Building on a previously reported phase I trial, we carried out a prospective phase II trial using stereotactic body radiation therapy (SBRT) in this population.Patients and MethodsEligible patients included clinically staged T1 or T2 (≤ 7 cm), N0, M0, biopsy-confirmed NSCLC. All patients had comorbid medical problems that precluded lobectomy. SBRT treatment dose was 60 to 66 Gy total in three fractions during 1 to 2 weeks.ResultsAll 70 patients enrolled completed therapy as planned and median follow-up was 17.5 months. The 3-month major response rate was 60%. Kaplan-Meier local control at 2 years was 95%. Altogether, 28 patients have died as a result of cancer (n = 5), treatment (n = 6), or comorbid illnesses (n = 17). Median overall survival was 32.6 months and 2-year overall survival was 54.7%. Grade 3 to 5 toxicity occurred in a total of 14 patients. Among patients experiencing toxicity, the median time to observation was 10.5 months. Patients treated for tumors in the peripheral lung had 2-year freedom from severe toxicity of 83% compared with only 54% for patients with central tumors.ConclusionHigh rates of local control are achieved with this SBRT regimen in medically inoperable patients with stage I NSCLC. Both local recurrence and toxicity occur late after this treatment. This regimen should not be used for patients with tumors near the central airways due to excessive toxicity.

scholarly journals PO-0883 Phase II trial of stereotactic body radiation therapy for abdomino-pelvic lymph node oligometastases

2019 ◽  
Vol 133 ◽  
pp. S466
Author(s):  
C. Franzese ◽  
T. Comito ◽  
A. Tozzi ◽  
F. De Rose ◽  
P. Navarria ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Lymph Node ◽  
Phase Ii ◽  
Stereotactic Body Radiation Therapy ◽  
Phase Ii Trial ◽  
Pelvic Lymph Node ◽  
Stereotactic Body Radiation
Sign in / Sign up

Export Citation Format

Share Document